A Study of LY2523355 in Participants With Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: LY2523355|DRUG: ixabepilone|DRUG: pegfilgrastim|DRUG: filgrastim
Sponsor: Eli Lilly and Company